RESEARCH PAPER
ApoE genotype as risk factors for Alzheimer’s disease in the population of Lublin region, Poland
| 1 | University Memory and Cognition Center, Case Western Reserve University, Cleveland, Ohio, USA; Department of Neurodegenerative Diseases Institute of Agricultural Medicine, Lublin, Poland |
CORRESPONDING AUTHOR
Katarzyna Gustaw-Rothenberg
MD, PhD, Department of Neurodegenerative Diseases, Institute of Agricultural Medicine, Jaczewskiego 2, 20-090 Lublin, Poland.
MD, PhD, Department of Neurodegenerative Diseases, Institute of Agricultural Medicine, Jaczewskiego 2, 20-090 Lublin, Poland.
J Pre Clin Clin Res. 2008;2(2):133–136
KEYWORDS
ABSTRACT
There is much data concerning ApoE in the pathology of Alzheimer’s disease. This study examines how ApoE genotype contributes to a risk for Alzheimer’s disease in the population of the Lublin region in Poland. The data were obtained as part of a population based BERCAL (Epidemiologic study of Alzheimer’s diseases and other forms of dementia in the population of Lublin region) study. Odds ratios (ORs) and 95% confidence intervals (CIs) for AD, adjusted for age, were calculated for ApoE genotypes. Epsilon3/epsilon3 genotype was the most prevalent genotype in both examined groups. Epsilon2/epsilon2 and epsilon4/epsilon4 were the least prevalent. Among subjects, the risk of AD was significantly reduced for people with genotypes epsilon2/epsilon2. The same significant result was noticed where results were recalculated so that the presence of at least one epsilon2 allele was taken into account, without any epsilon 4 allele in each person. Increased risk with occurrence of epsilon 4 allele is not shown. Increased risk in epsilon 4 carriers was observed. The test did not reach the level of power required. This study suggests that the well known genetic factor, mainly ApoE, even if of noticeable importance, may not be a main risk factor among the population of the Lublin region in Poland.
REFERENCES (29)
1.
Murayama S, and Saito Y: Neuropathological diagnostic criteria for Alzheimer’s disease. Neuropathology 2004, 24, 254-260.
2.
McKeel DW Jr, Price JL, Miller JP, Grant EA, Xiong C, Berg L, Morris JC: Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J Neuropathol Exp Neurol 2004, 63, 1028-1037.
3.
Gandy S: The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005 May, 115(5).
4.
Hardy J: Has the amyloid cascade hypothesis for Alzheimer’s disease been proved? Curr Alzheimer Res 2006 Feb, 3(1), 71-73.
5.
Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD: Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 2008 Feb 26, 178(5), 548-556.
6.
Muller T, Meyer HE, Egensperger R, Marcus K: The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer’s disease. Prog Neurobiol 2008 Aug, 85(4), 393-406.
7.
Resende R, Ferreiro E, Pereira C, Resende de Oliveira C: Neurotoxic eff ect of oligomeric and fi brillar species of amyloid-beta peptide1-42: involvement of endoplasmic reticulum calcium release in oligomerinduced cell death. Neuroscience 2008 Aug 26, 155(3), 725-737.
8.
Delacourte A: Tau pathology and neurodegeneration: an obvious but misunderstood link. J Alzheimers Dis 2008 Aug, 14(4), 437-440.
9.
Tang BL, Liou YC: Novel modulators of amyloid-beta precursor protein processing. J Neurochem 2007 Jan, 100(2), 314-323.
10.
Pericak-Vance MA, Bebout JL, Gaskell PC Jr, Yamaoka LH, Hung WY, Alberts MJ, Walker AP, Bartlett RJ, Haynes CA, Welsh KA, et al.: Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991 Jun, 48(6), 1034-1050.
11.
Schellenberg GD, Pericak-Vance MA, Wijsman EM, Moore DK, Gaskell PC Jr, Yamaoka LA, Bebout JL, Anderson L, Welsh KA, Clark CM, et al.: Linkage analysis of familial Alzheimer disease, using chromosome 21 markers. Am J Hum Genet 1991 Mar, 48(3), 563-583.
12.
Saunders AM, Strittmatter WJ, Schmechel p, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Helette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993, 43, 1467-1472.
13.
Roses AD: On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis 2006, 9(3 Suppl), 361-366.
14.
Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott WK, Conneally PM, Vance JM, Haines JL: Identifi cation of novel genes in late-onset Alzheimer’s disease. Exp Gerontol 2000 Dec, 35(9-10), 1343-1352.
15.
Riley KP, Snowdon DA, Saunders AM, Roses AD, Mortimer JA, Nanayakkara N: Cognitive function and apolipoprotein E in very old adults: fi ndings from the Nun Study. J Gerontol B Psychol Sci Soc Sci 2000 Mar, 55(2), 69-75.
16.
Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, et al.: Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofi brils. Isoform apoE4 associates more effi ciently than apoE3. J Clin Invest 1994 Aug, 94(2), 860-869.
17.
Carter DB: The interaction of amyloid-beta with ApoE. Subcell Biochem 2005, 38, 255-272.
18.
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J,Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993 Mar 1, 90(5), 1977-1981.
19.
Burke JR, Roses AD: Genetics of Alzheimer’s disease. Int J Neurol 1991-1992, 25-26, 41-51.
20.
Mayeux R, Stem Y, Ottman R, Tatemichi TK, Tang MX, Maestre G, Ngai C, Tycko B, Ginsberg H. The apolipoprotein 04 allele in patients with Alzheimer’s disease. Ann Neurol 1993, 34, 752- 754.
21.
Carmo Martins M, Lima Faleiro L, Rodrigues MO, Albergaria I, Fonseca A: Infl uence of the APOE genotypes in some atherosclerotic risk factors. Acta Med Port 2008 Sep-Oct, 21(5), 433-440.
22.
Gustaw K, Woźnica I, Bylina J: ROZPOWSZECHNIENIE ZESPOLOW OTEPIENNYCH W TYM CHOROBY ALZHEIMERA W POPULACJI MIESZKANCOW WOJEWODZTWA LUBELSKIEGO. Medycyna Ogolna 2008, 14 (XLIII), 4, 381-394.
23.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed). American Psychiatric Association 2000. Washington, DC, USA. Text Revision (DSM-IV-TR).
24.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDSADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 1984, 34, 939-944.
25.
Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplifi cation and cleavage with HhaI.J Lipid Res 1990 Mar, 31(3), 545-548.
26.
Hixson JE, Vernier DT, Powers PK: Detection of SstI restriction site polymorphism in human APOC3 by the polymerase chain reaction. Nucleic Acids Res 1991 Jan 11, 19 (1), 196.
27.
Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA: APOE, vascular pathology, and the AD brain. Neurology 2005 Jul 26, 65(2), 259-265.
28.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Eff ects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997 Oct 22-29, 278(16), 1349-1356.
29.
Mortimer JA: Epidemiology of dementia: cross-cultural comparisons. Adv Neurol 1990, 51, 27-33.
The Journal of Pre-Clinical and Clinical Research welcomes article
submissions and does not charge a publication fee.
Submit your article today and gain worldwide visibility for your article.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.